VolitionRx Limited (NYSE AMERICAN: VNRX) (Volition), a multi-national epigenetics company, announced on Tuesday that it has named Dr Andrew Retter as its new Chief Medical Officer, effective 1 April 2024.
In the new role, Dr Retter is to offer medical leadership at the company and ensure that the firm's scientific and clinical efforts are aligned with patient requirements.
Andrew is serving as an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust in London. He has worked as a Consultant and heads Clinical Governance in Critical Care, and deals with the management of severe respiratory failure, ECMO and thrombosis in critical care.
Cameron Reynolds, President and Group Chief Executive Officer at Volition, said: "We are delighted to welcome Andrew to Volition. Dr Retter is a leading expert in Intensive Care Medicine and Haematology. As Chief Medical Officer he will be vital to our success - ensuring the needs of the patient are placed at the heart of our research, development and commercialisation activities."
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
EydisBio receives USD2.6m SBIR grant from NIH's National Heart, Lung, and Blood Institute
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
BerGenBio partners with Tempus to advance lung cancer drug
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults